| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $16.0M | +4.3% | -34.7% |
| SG&A Expense | $7.8M | +19.0% | +128.1% |
| Operating Income | -$23.8M | -8.7% | +14.9% |
| Net Income | -$20.3M | -12.2% | +20.3% |
| EPS (Basic) | -$0.46 | +99.9% | +91.9% |
| EPS (Diluted) | -$0.46 | +99.9% | +91.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $50.8M | +24.0% | +42.2% |
| Current Assets | $252.3M | -5.4% | — |
| Total Assets | $339.3M | -3.6% | — |
| Current Liabilities | $9.9M | +30.5% | — |
| Total Liabilities | $17.6M | +12.7% | — |
| Stockholders' Equity | $321.7M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$49.7M | — | — |
| Capital Expenditures | $173K | — | — |
| Investing Cash Flow | -$141.3M | — | — |
| Financing Cash Flow | $204.1M | — | — |
| Free Cash Flow | -$49.8M | — | — |
| -4.4% |
| +316.5% |